- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06539728
Validation of Texture Changing Coatings for Use in At-Home Rapid Tests
Validation of Texture-Changing Tactile Coatings for Potential Use in Accessible At-Home Care
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Charles Dhong, PhD
- Phone Number: 302-831-2828
- Email: cdhong@udel.edu
Study Contact Backup
- Name: Cynthia Papettas
- Phone Number: 302-279-6766
- Email: cpap@Udel.edu
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19711
- University of Delaware
-
Contact:
- Charles Dhong, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Visual Impairment: Participants should be blind or visually impaired for greater than 10 years, either congenitally or acquired.
- Tactile Aid Usage: Participants must use tactile aids regularly.
- Mathematical Knowledge: Participants should have a basic understanding of mathematical plots, equivalent to at least high school geometry.
Exclusion Criteria:
- Limb Conditions: Participants with amputations or outer extremity conditions affecting hand use will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Interaction with Coated Surfaces
Participants in this arm will interact with the device and surface coated with the polymer-antibody coating.
Subjects will be trained with a "positive" test and "negative" test prior to device testing.
Subjects will then administer the synthetic saliva themselves and asked to determine if there was COVID antigen in the saliva by touching the device to compare the test patch to the positive and negative control patches.
Subjects will also rate device usability.
|
Participants will drop a saline solution with proteins onto the testing device.
They will wait for it to dry and then report on the tactile sensation and overall feel of the surface.
Feedback will include comparisons with the two reference surfaces.
The primary goal is to determine the presence of mock COVID antigen in synthetic saliva using the device, which aligns with the goals of diagnostic testing.
Participants may have biomechanical measurements recorded, such as placing samples on a scale to measure downward force or using medical tape with a flexible wire to track finger motion.
These measurements are likely aimed at objectively assessing how participants interact with the surfaces and their physical responses to tactile stimuli.
Participants may alternatively be asked to perform standardized psychophysical tasks, such as Two Alternative Forced Choice tests, Odd-Man Out tests, or Magnitude Estimation tests.
These tasks will provide structured comparisons and quantitative data on participants' perception and preferences regarding tactile qualities.
The tasks are designed to evaluate participants' perception and preferences regarding tactile qualities, which involves behavioral responses to sensory stimuli.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Success rate of identifying whether the model test is positive or negative
Time Frame: Through study completion, an average of 1 year
|
After familiarization, test trials will involve participants dropping a test solution onto the device with a test slab as well as positive and negative control slabs.
They will be asked to identify whether the test is positive or negative, based on how the test slab feels to the touch compared to the controls.
Participants will be evaluated on whether or not their response is correct.
This will be repeated 10 times per participant to record a percentage of success.
|
Through study completion, an average of 1 year
|
|
Response time of each trial of a participant identifying whether the model test is positive or negative
Time Frame: Through study completion, an average of 1 year
|
A Qualtrics form will be used to record participant responses.
Each trial will have its own page on the form during data collection.
A trial will begin when the test administrator opens its page, and participants will be prompted to decide whether the device is displaying a positive or negative result.
Once participants choose, the administrator will select their answers on the form, and the time to the last click will be recorded as their response time.
This will be repeated 10 times.
|
Through study completion, an average of 1 year
|
|
Usability feedback
Time Frame: Through study completion, an average of 1 year
|
Subjects participating in the clinical trial will be invited to provide feedback on the usability and their preferences regarding the tactile aid introduced in the study. The assessment will be conducted using a modified Likert scale. This outcome aims to gather subjective experiences related to the use of new tactile aids throughout the trials. Throughout the study, participants will be consistently asked to comment on the usability and their preferences based on the tactile aid. This ongoing feedback will enable a comprehensive understanding of their experiences over time. Modified Likert Scale: Strongly Disagree Disagree Somewhat Disagree Neutral Somewhat Agree Agree Strongly Agree Extremely Agree Exceptionally Agree Title: Usability of Tactile Aid Min: 1 Max: 9 Higher the score, the better the outcome/ usability of the tactile aid. |
Through study completion, an average of 1 year
|
|
General feedback
Time Frame: Through study completion, an average of 1 year
|
Subjects participating in the clinical trial will be invited to provide feedback on the usability and their preferences regarding the tactile aid introduced in the study.
The assessment will be conducted by asking participants for general feedback on the device they used.
Throughout the study, participants will be consistently asked to comment on the usability and their preferences based on the tactile aid.
This ongoing feedback will enable a comprehensive understanding of their experiences over time.
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2181777
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blindness
-
University Hospital, Clermont-FerrandTerminatedVisual Deficiency | Congenital Blindness | Acquired BlindnessFrance
-
Salgado Institute of Integral HealthCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.UnknownBlindness, Acquired | Blindness CongenitalBrazil
-
Shanghai Vision Science Engineer Medical Equipment...Not yet recruitingCorneal Blindness | Keratoprosthesis
-
University of California, Los AngelesActive, not recruiting
-
Smith-Kettlewell Eye Research InstituteRecruitingBlindness | Low Vision | Blindness, Acquired | Blindness, CompleteUnited States
-
Universidad de ExtremaduraNot yet recruitingDisabilities | Visual Impairment and Blindness (Excl Colour Blindness)
-
Fondation Ophtalmologique Adolphe de RothschildActive, not recruitingStroke | Hemianopia | Homonymous Hemianopia | Cortical BlindnessFrance
-
University of the Incarnate WordNational Eye Institute (NEI)CompletedColor Vision Defects | Color Blindness | Color Blindness, Red | Color Blindness, GreenUnited States
-
Wake Forest University Health SciencesNot yet recruitingHemianopia, Homonymous | Cortical Blindness, Unspecified Side of BrainUnited States
-
Bahçeşehir UniversityCompletedBlindness CongenitalTurkey
Clinical Trials on Interaction with Mock COVID-19 Rapid Antigen Test and Reference Surfaces
-
Mach-E B.V.Completed
-
Cannabis Research AssociatesNot yet recruiting
-
Therma Bright IncRecruitingCOVID-19United States
-
University of California, Los AngelesCompleted
-
Columbia UniversityTerminated
-
Somerset NHS Foundation TrustUnknown
-
University of British ColumbiaProvidence Health & Services; Vancouver Airport Authority; WestJet Airlines; KLM...Completed
-
EDP BiotechParagon Rx Clinical, Inc.; iCura Diagnostics, LLCCompleted
-
MP Biomedicals, LLCEDP BiotechCompletedCOVID-19 | SARS-CoV2 InfectionUnited States